文献速递心力衰竭与心肌病血脂与心血管预防

COVID-19相关急性心肌炎的患病率、特征与结局

Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.
PubMed 文献 · Circulation · 2022-04-11

基于美欧23家医院回顾性队列,56 963例COVID-19住院患者中评估疑似急性心肌炎112例,确定/很可能急性心肌炎54例。患病率确定/很可能为2.4/1000住院,含可能病例为4.1/1000。中位年龄38岁,38.9%女性,38.9%呈暴发性表现,院内死亡或临时机械循环支持复合终点20.4%,120天估算死亡率6.6%,伴肺炎者15.1% versus 无肺炎者0%(P=0.044)。

要点

  • COVID-19住院患者中确定/很可能急性心肌炎患病率约2.4/1000。
  • 多数急性心肌炎无COVID-19相关肺炎,常伴血流动力学不稳定。
  • 合并肺炎者120天死亡率显著高于无肺炎者。

核心结论

  • COVID-19住院患者中急性心肌炎患病率估计为2.4–4.1/1000。
  • 急性心肌炎多无肺炎且常并发血流动力学不稳定,结局因是否伴肺炎而异。

研究设计与样本

  • 回顾性队列研究,纳入美国与欧洲23家医院56 963例COVID-19住院患者。
  • 评估疑似急性心肌炎112例,确定/很可能急性心肌炎54例,其中心内膜活检支持17例(31.5%),心脏磁共振支持50例(92.6%)。

主要发现

  • 确定/很可能急性心肌炎患病率2.4/1000住院,含可能病例为4.1/1000。
  • 确定/很可能病例中位年龄38岁,女性占38.9%,入院最常见症状为胸痛(55.5%)和呼吸困难(53.7%)。
  • 31例(57.4%)无COVID-19相关肺炎,21例(38.9%)呈暴发性表现需正性肌力支持或临时机械循环支持。
  • 院内死亡或临时机械循环支持复合终点发生率为20.4%。
  • 120天估算死亡率6.6%,伴肺炎者15.1% versus 无肺炎者0%(P=0.044);左室射血分数中位值从入院40%改善至出院55%(n=47,P<0.0001)。

关键数值与推荐

  • 急性心肌炎诊断基于心内膜活检或肌钙蛋白升高加心脏磁共振典型征象。
  • 皮质类固醇使用频率为55.5%。

临床怎么用

  • COVID-19住院患者出现胸痛、呼吸困难或血流动力学不稳定时应警惕急性心肌炎。
  • 合并肺炎的急性心肌炎患者短期死亡风险更高,需加强监护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19-associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. METHODS: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19-associated AM. RESULTS: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19-associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia (P=0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge (n=47; P<0.0001) similarly in patients with or without pneumonia. Corticosteroids were frequently administered (55.5%). CONCLUSIONS: AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ammirati E, Lupi L, Palazzini M, et al. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. Circulation. 2022. PMID: 35404682. doi:10.1161/CIRCULATIONAHA.121.056817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。